News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
274,171 Results
Type
Article (14380)
Company Profile (105)
Press Release (259678)
Multimedia
Podcasts (67)
Webinars (13)
Section
Business (88330)
Career Advice (465)
Deals (15404)
Drug Delivery (74)
Drug Development (36773)
Employer Resources (51)
FDA (6392)
Job Trends (6235)
News (150809)
Policy (14149)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (443)
Accelerated approval (14)
Adcomms (8)
Allergies (71)
Alliances (23325)
ALS (56)
Alzheimer's disease (481)
Antibody-drug conjugate (ADC) (101)
Approvals (6581)
Artificial intelligence (205)
Autoimmune disease (46)
Automation (13)
Bankruptcy (151)
Best Places to Work (4372)
BIOSECURE Act (9)
Biosimilars (120)
Biotechnology (40)
Bladder cancer (38)
Brain cancer (30)
Breast cancer (174)
Cancer (1333)
Cardiovascular disease (169)
Career advice (418)
Career pathing (13)
CAR-T (51)
CDC (6)
Cell therapy (158)
Cervical cancer (9)
Clinical research (32073)
Collaboration (743)
Compensation (329)
Complete response letters (34)
COVID-19 (784)
CRISPR (46)
C-suite (451)
Cystic fibrosis (58)
Data (1844)
Denatured (18)
Depression (45)
Diabetes (127)
Diagnostics (1388)
Digital health (10)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (120)
Drug pricing (115)
Drug shortages (12)
Duchenne muscular dystrophy (82)
Earnings (33528)
Editorial (21)
Employer branding (5)
Employer resources (47)
Events (39016)
Executive appointments (538)
FDA (7496)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (443)
Gene editing (75)
Generative AI (18)
Gene therapy (172)
GLP-1 (444)
Government (1409)
Grass and pollen (4)
Guidances (164)
Healthcare (3578)
HIV (12)
Huntington's disease (10)
IgA nephropathy (39)
Immunology and inflammation (69)
Immuno-oncology (15)
Indications (55)
Infectious disease (851)
Inflammatory bowel disease (74)
Inflation Reduction Act (7)
Influenza (25)
Intellectual property (115)
Interviews (60)
IPO (5917)
IRA (33)
Job creations (2055)
Job search strategy (374)
JPM (30)
Kidney cancer (9)
Labor market (28)
Layoffs (207)
Leadership (8)
Legal (3457)
Liver cancer (22)
Longevity (8)
Lung cancer (184)
Lymphoma (124)
Machine learning (13)
Management (17)
Manufacturing (421)
MASH (70)
Medical device (1306)
Medtech (1313)
Mergers & acquisitions (9909)
Metabolic disorders (444)
Multiple sclerosis (48)
NASH (14)
Neurodegenerative disease (83)
Neuropsychiatric disorders (38)
Neuroscience (895)
Neurotech (1)
NextGen: Class of 2026 (1593)
Non-profit (602)
Now hiring (18)
Obesity (233)
Opinion (148)
Ovarian cancer (39)
Pain (110)
Pancreatic cancer (52)
Parkinson's disease (80)
Partnered (11)
Patents (224)
Patient recruitment (121)
Peanut (12)
People (29790)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase 1 (8323)
Phase 2 (13539)
Phase 3 (12237)
Pipeline (1978)
Policy (135)
Postmarket research (1401)
Preclinical (3345)
Press Release (25)
Prostate cancer (86)
Psychedelics (16)
Radiopharmaceuticals (136)
Rare diseases (360)
Real estate (2660)
Recruiting (20)
Regulatory (10987)
Reports (15)
Research institute (576)
Resumes & cover letters (55)
Rett syndrome (5)
RNA editing (6)
RSV (20)
Schizophrenia (69)
Series A (83)
Series B (54)
Service/supplier (2)
Sickle cell disease (47)
Special edition (10)
Spinal muscular atrophy (81)
Sponsored (9)
Startups (1653)
State (2)
Stomach cancer (5)
Supply chain (51)
Tariffs (68)
The Weekly (47)
Vaccines (242)
Venture capital (35)
Weight loss (143)
Women's health (28)
Worklife (4)
Date
Last 7 days (212)
Last 30 days (663)
Last 365 days (10404)
2026 (1166)
2025 (10735)
2024 (12515)
2023 (14263)
2022 (19568)
2021 (20077)
2020 (19040)
2019 (14892)
2018 (11727)
2017 (13898)
2016 (13134)
2015 (15474)
2014 (12420)
2013 (10593)
2012 (11396)
2011 (11923)
2010 (10890)
Location
Africa (319)
Alabama (19)
Alaska (1)
Arizona (78)
Arkansas (3)
Asia (20914)
Australia (2690)
California (3207)
Canada (1499)
China (561)
Colorado (146)
Connecticut (133)
Delaware (126)
Europe (40927)
Florida (611)
Georgia (63)
Hawaii (1)
Idaho (10)
Illinois (352)
India (45)
Indiana (241)
Iowa (2)
Japan (251)
Kansas (77)
Kentucky (20)
Louisiana (4)
Maine (2)
Maryland (425)
Massachusetts (2625)
Michigan (46)
Minnesota (168)
Mississippi (1)
Missouri (33)
Montana (8)
Nebraska (7)
Nevada (16)
New Hampshire (8)
New Jersey (1415)
New Mexico (7)
New York (913)
North Carolina (628)
North Dakota (2)
Northern California (1462)
Ohio (81)
Oklahoma (5)
Oregon (18)
Pennsylvania (728)
Puerto Rico (13)
Rhode Island (17)
South America (509)
South Carolina (10)
Southern California (1403)
Tennessee (53)
Texas (457)
United States (12823)
Utah (60)
Virginia (161)
Washington D.C. (42)
Washington State (225)
West Virginia (1)
Wisconsin (39)
Wyoming (1)
274,171 Results for "alnylam pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Alnylam Pharmaceuticals Announces Changes to Board of Directors
December 3, 2025
·
7 min read
Press Releases
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress
February 12, 2026
·
19 min read
Press Releases
Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact
January 12, 2026
·
11 min read
Earnings
‘Very Impressive’ Amvuttra ATTR-CM Sales Send Alnylam Soaring
In its first commercial quarter for ATTR-cardiomyopathy, Alnylam’s Amvuttra reached roughly 1,400 patients and made more than $490 million.
August 1, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results
January 29, 2026
·
1 min read
Press Releases
Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
·
2 min read
Press Releases
Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress
October 31, 2025
·
19 min read
Cardiovascular disease
Alnylam’s Amvuttra Approved as First RNAi Silencer for Rare Type of Cardiomyopathy
The FDA approval of Alnylam’s Amvuttra sets up a three-way race with Pfizer and BridgeBio, which both market transthyretin stabilizers for transthyretin amyloid cardiomyopathy.
March 20, 2025
·
8 min read
·
Heather McKenzie
Press Releases
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027
December 12, 2025
·
4 min read
Press Releases
Alnylam to Webcast Presentations at Upcoming November 2025 Investor Conferences
November 5, 2025
·
1 min read
1 of 27,418
Next
